Malnutrition and Low Muscle Mass in Patients with Gastrointestinal Cancer Undergoing Surgery: is There an Association with Tumor Location?

https://doi.org/10.32635/2176-9745.RBC.2024v7on2.4630

Desnutrição e Baixa Massa Muscular em Pacientes com Câncer Gastrointestinal Submetidos à Cirurgia: Existe Associação com a Localização do Tumor?

Desnutrição y Baja Masa Muscular en Pacientes con Cáncer Gastrointestinal Sometidos a Cirugía: ¿Existe Asociación con la Ubicación del Tumor?

Juliane Alves da Silva; Viviane Dias Rodrigues; Renata Brum Martucci; Andresa da Silva Couto; Aline Barcellos Barreto; Nilian Carla Souza

ABSTRACT

Introduction: Depletion of nutritional status and reduction of muscle mass are common features in cancer patients. Objective: To compare nutritional status, muscle mass, and strength in patients with upper gastrointestinal tract cancer and colorectal cancer. Method: Subset of a prospective cohort study involving patients with gastrointestinal tract cancer undergoing surgery. Nutritional assessment included patient-generated subjective global assessment (PG-SGA) and body mass index (BMI). Body composition was assessed by computed tomography, and handgrip strength, by dynamometry. Sarcopenia was defined by reduced muscle strength and skeletal muscle index or reduced muscle strength and skeletal muscle radiodensity. Results: The study included 52 patients, 54% males, 56% older adults, 67% had colorectal cancer, and 68% were in stages 3 and 4 of the disease. Although the majority of the individuals (42%) were classified as eutrophic/normal weight according to BMI, 56% were at nutritional risk or malnourished according to PG-SGA. Only three patients had sarcopenia. A higher incidence of patients with upper gastrointestinal tract cancer were underweight and exhibited low skeletal muscle mass compared to patients with colorectal cancer (58% and 42%, \( p = 0.031 \); 60% and 40%, \( p = 0.018 \), respectively). Conclusion: The analysis revealed a higher prevalence of underweight and low skeletal muscle mass in patients with upper gastrointestinal tract cancer.

Key word: Gastrointestinal Neoplasms/surgery; Colorectal Neoplasms/surgery; Sarcopenia/surgery; Nutritional Status; Body Composition.
INTRODUCTION

Cancer is a relevant global health problem and one of the main causes of premature death worldwide. For each year of the triennium 2023-2025, 704 thousand new cases were estimated for Brazil, standing out 66,000 (9.4%) cases of colorectal cancer, 30,000 cases (4.4%) of gastric tumor, 10,990 (1.56%) new cases of esophageal tumors and 10,980 of pancreas cancer.

Colorectal cancer is ranked third among the most frequent with higher rates in the Southeast region followed by gastric cancer in fifth, esophagus cancer in thirteenth and pancreas cancer in the fourteenth position, the last two the most incident types in the South region. Cancer-related malnutrition is a condition arising from the activation of systemic inflammation that may cause anorexia and tissue breakdown that can, in turn, result in significant loss of body weight, alterations in body composition and declining physical function. In addition, factors related to the tumor itself, staging and effect of the treatment contribute to the compromise of the nutritional status, negatively impacting survival, response to the treatment, surgical outcomes and quality of life.

Sarcopenia is a condition characterized by loss of muscle mass and function associated with ageing, called primary sarcopenia. However, it can occur in individuals with chronic diseases as cancer, the secondary sarcopenia. Actually, low skeletal muscle mass and more recently, sarcopenia have been investigated as associated with postoperative complications and lower survival of patients with cancer submitted to gastrointestinal tract surgeries.

Studies associating muscle mass and strength with tumor site in patients submitted to surgical resection are scarce, notwithstanding the literature-based findings indicating that specifically, upper gastrointestinal cancer is one of the types with high prevalence of malnutrition. The objective of this study is to compare the nutritional status, muscle mass and strength in patients with upper gastrointestinal tract cancer (esophagus, stomach and pancreas) and colorectal cancer submitted to surgery.

METHOD

Prospective cohort study with patients diagnosed with gastrointestinal cancer assisted at a tertiary hospital in Rio de Janeiro. It is a subsample of the project “Nutritional status, body composition and functionality of patients with gastrointestinal tract cancer: a prospective study”, with the objective of monitoring weight changes, body composition and functionality in the course of the oncologic treatment. The Institutional Review Board (IRB) approved the study, report number 6758988 (CAAE (submission for ethical review): 46304721.4.0000.5274) in compliance with Directive 466/2012 of the National Health Council.

The inclusion criteria were adults (age >20 years) diagnosed with primary tumor of the gastrointestinal tract (esophagus, stomach, pancreas, colorectal) submitted to surgery who attended outpatient nutrition pre-surgery consultation. The exclusion criteria were individuals in palliative care referred to clinical treatment (chemotherapy and radiotherapy), performance status >3 and synchronous tumor.

Patients who would be submitted to elective surgery attended initial consultation at the nutrition outpatient prior to the surgery between June 2021 and July 2023 according to the routine determined by the institution's Nutrition and Dietary Sector. Those who accepted to join the study were asked to sign the informed consent form at the consultation followed by nutritional and muscle strength evaluation. The patients were briefed about feeding according to the type of pathology and specific individual needs. Those in nutritional risk or malnourished were guided about oral or enteral nutritional support according to the outpatient routine implemented according to the standard operational procedures of the same sector.

Demographic and clinical data were collected from the electronic chart with cancer family history, comorbidities, nutritional therapy, tumor site, date of the diagnosis, performance status, clinical staging and oncologic treatment data.

The Patient-Generated Subjective Global Assessment (PG-SGA) translated and available at https://pt-global.org/ was applied. The tool is divided in two parts. The first is responded by the patient or caregiver with questions about weight, food intake, symptoms and functional capacity and the second, factors associated with increase of metabolic demand were evaluated further to physical examination. The patients were classified as well nourished (A), nutritional risk or moderate malnutrition (B) and severe malnutrition (C) and all the scores were added up. In addition to identifying changes of the nutritional status, the instrument can be applied to design specific nutritional intervention measures.

Body weight and height were measured to calculate the body mass index (BMI, kg/m²) according to the World Health Organization (WHO) for adults and the Pan American Health Organization (PAHO) for Older Adults.

Skeletal muscle mass was evaluated by computed tomography (CT) at the level of the third lumbar vertebra (L3), utilizing the attenuation range -29HU to...
+150HU\textsuperscript{22} through the software Slice-O-Matic\textsuperscript{23}, version 5.0, (Tomovision’, Canada). The skeletal muscle area obtained (cm\textsuperscript{2}) was utilized to calculate the skeletal muscle index (SMI) defined as the ratio between the muscle area (cm\textsuperscript{2}) and the height (m\textsuperscript{2}). In addition, the mean of skeletal muscle radiodensity (SMD) by the mean of the attenuation of the skeletal muscle was calculated within the range -29 to +150 HU\textsuperscript{22}.

Muscle strength was evaluated by the handgrip strength (HGS) with the dynamometer Jamar\textsuperscript{*} (Sammons Preston’, USA) with the patients seated with the elbow flexed at 90°. Each hand was measured three times and the highest measure was utilized\textsuperscript{22}.

Patients with reduced HGS and SMI or reduction of HGS and SMD were classified with sarcopenia since SMI and SMD are utilized for diagnostic confirmation according to the European Working Group on Sarcopenia in Older People\textsuperscript{6}. Cutoff values below the first tertile were defined: for men, HGS < 29 kg, SMI < 44.8 cm\textsuperscript{2}/m\textsuperscript{2} and SMD < 35.6 HU and for women, HGS < 18 kg, SMI < 36.8 cm\textsuperscript{2}/m\textsuperscript{2} and SMD < 31.8 HU.

The anonymized data were processed with the software SPSS\textsuperscript{24} version 21 and the results were presented in aggregate to protect the patient’s identity. The Kolgomorov-Smirnov\textsuperscript{25} test was applied to verify the normality of the distributions presented as mean and standard deviation for the continuous variables with normal distribution, median and interquartile range for normal distribution and absolute and percentile frequency for categorical variables. The chi-square test (X\textsuperscript{2}) was utilized to compare the categorical variables (PG-SGA A versus B and C, BMI low weight versus absence of low weight, SMI, SMD and HGS < 1 tertile versus SMI, SMD and HGS > 1 tertile) with level of significance of 5% (p < 0.05).

RESULTS

The study was conducted with 52 patients (24 women and 28 men) with median age of 61.5 years (interquartile range: 50.5; 66 years), 56% older adults and 44% adults (Table 1). The flowchart portrays the number of patients enrolled and excluded (Figure 1).

The main comorbidities were arterial hypertension (27%, n = 14) and association between diabetes mellitus and hypertension (17%, n = 9), none of the patients presented diabetes mellitus alone. More than half of the sample consisted of patients with restriction to perform extenuating physical activities (performance status 1 and 2) (73%; n = 38). This same percentage was diagnosed with colorectal tumor (67%; n = 35) and 33% (n = 17) with upper GIT tumors (esophagus, stomach and pancreas). The most prevalent staging were III and IV, responding for 68% of the sample (n = 34) (Table 1). In addition, 77% (n = 40) of the sample were in oral nutritional therapy and nearly 19% (n = 10), in enteral nutritional therapy.

According to Table 2, BMI, HGS, SMI and SMD were similar, regardless of tumor site, except for males with colorectal tumor who presented higher SMI compared to individuals with upper GIT tumors (p = 0.021).

However, 58% (n = 7) of the patients with upper GIT have low weight according to BMI, different from patients with colorectal tumor where 75% (n = 30) do not share this same weight (p = 0.031). In addition, great part of the patients with upper GIT presented SMI < 1 tertile (60%; n = 6), while 82% (n = 18) of the individuals with colorectal cancer presented SMI > 1 tertile (p = 0.018) (Table 3). Among the patients without low weight (classified as satisfactory/eutrophy or overweight/obesity according to BMI), four had SMI < 1 tertile, ten, HGS < 1 tertile and eight, SMD < 1 tertile.

DISCUSSION

The occurrence of low weight in upper GIT tumors was higher than in colorectal tumors. For patients with cancer, nutritional status may be associated with tumor location, staging and type of cancer treatment. Malnutrition is a frequent condition in patients with GIT cancer compared to other types of cancer\textsuperscript{22} and can affect up to 80% of patients with upper GIT cancer due to poor absorption, intestinal obstruction, surgical resection therapies and systemic treatment\textsuperscript{26-28}.

In addition, SMI < 1 tertile for the group of patients with upper GIT cancer occurred more frequently than for the group of colorectal cancer (60% versus 40%; p < 0.05), but the occurrence of SMD < 1 tertile was similar for both groups (50%). McGovern et al. found similar reduction of
SMD for intestine, esophagus and pancreas cancers (52%, 54% and 55%, respectively)\textsuperscript{31}. However, the occurrence was higher for patients with stomach tumors (71%)\textsuperscript{29}, but the reduction of SMI for upper gastrointestinal tumors was lower than in the present study (esophagus, 49%, stomach, 35% and pancreas, 32%)\textsuperscript{28}. Murnane et al.\textsuperscript{30} found a reduction of 56% of SMI in patients submitted to radical resection of esophagus and stomach and Carvalho et al.\textsuperscript{31} did not find statistical differences in the reduction of colorectal and gastric tumors in patients submitted to surgery (20% and 13%, respectively)\textsuperscript{31}.

Cancer related low muscle mass results from pro-inflammatory status of the disease itself, which favors the reduction of protein synthesis and high degradation of proteins in addition to high energy expenditure which may or may not be associated with the reduction of food intake\textsuperscript{32-33}. Studies demonstrate that inflammatory cytokines derived from the tumor are involved in the pathogenesis of sarcopenia\textsuperscript{34-37}. Despite being different clinical phenotypes\textsuperscript{37-38}, fat infiltration into the muscle known as myosteatosis and depletion of muscle mass, if concomitant, can lead to worst outcomes\textsuperscript{37,39-40}.

More than half of the study sample presented satisfactory/eutrophy BMI. A study with older adults submitted to surgical resection of gastrointestinal tumors have also found high occurrence of eutrophy followed by overweight\textsuperscript{5}. On the other hand, 56% presented risk of malnutrition or malnutrition according to PG-SGA, which includes symptoms that can affect food intake further to other factors related to the risk of malnutrition even if no significant changes of the nutritional status according to BMI occur\textsuperscript{41}.

Measurement of body weight and calculation of BMI are commonly utilized in clinical practice, but these measures do not provide information about the contributions of fat mass and muscle mass or changes in these compartments that can reflect the actual nutritional status of the individual\textsuperscript{42}. In addition to the evaluation of the muscle mass, studies indicate the relevance of the diagnosis of sarcopenia in this group of patients; a cross-sectional study with 21 patients submitted to gastrectomy found no significant changes in the reduction of SMI for patients with stomach tumors (71%)\textsuperscript{29}, but the reduction of SMI for upper gastrointestinal tumors was lower than in the present study (esophagus, 49%, stomach, 35% and pancreas, 32%)\textsuperscript{28}. Murnane et al.\textsuperscript{30} found a reduction of 56% of SMI in patients submitted to radical resection of esophagus and stomach and Carvalho et al.\textsuperscript{31} did not find statistical differences in the reduction of colorectal and gastric tumors in patients submitted to surgery (20% and 13%, respectively)\textsuperscript{31}.

Cancer related low muscle mass results from pro-inflammatory status of the disease itself, which favors the reduction of protein synthesis and high degradation of proteins in addition to high energy expenditure which may or may not be associated with the reduction of food intake\textsuperscript{32-33}. Studies demonstrate that inflammatory cytokines derived from the tumor are involved in the pathogenesis of sarcopenia\textsuperscript{34-37}. Despite being different clinical phenotypes\textsuperscript{37-38}, fat infiltration into the muscle known as myosteatosis and depletion of muscle mass, if concomitant, can lead to worst outcomes\textsuperscript{37,39-40}.

More than half of the study sample presented satisfactory/eutrophy BMI. A study with older adults submitted to surgical resection of gastrointestinal tumors have also found high occurrence of eutrophy followed by overweight\textsuperscript{5}. On the other hand, 56% presented risk of malnutrition or malnutrition according to PG-SGA, which includes symptoms that can affect food intake further to other factors related to the risk of malnutrition even if no significant changes of the nutritional status according to BMI occur\textsuperscript{41}.

Measurement of body weight and calculation of BMI are commonly utilized in clinical practice, but these measures do not provide information about the contributions of fat mass and muscle mass or changes in these compartments that can reflect the actual nutritional status of the individual\textsuperscript{42}. In addition to the evaluation of the muscle mass, studies indicate the relevance of the diagnosis of sarcopenia in this group of patients; a cross-sectional study with 21 patients submitted to gastrectomy...
Table 3. Nutritional status and body composition stratified by tumor site (n = 52)

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>Upper GIT (n = 17)a</th>
<th>Colorectal (n = 35)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low weight/malnutrition (n = 12)</td>
<td>7 (58%)</td>
<td>5 (42%)</td>
<td>0.031</td>
</tr>
<tr>
<td>Without low weight/malnutrition (n = 40)</td>
<td>10 (25%)</td>
<td>30 (75%)</td>
<td></td>
</tr>
<tr>
<td><strong>PG-SGA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (n = 23)</td>
<td>5 (22%)</td>
<td>18 (78%)</td>
<td>0.134</td>
</tr>
<tr>
<td>B &amp; C (n = 29)</td>
<td>12 (41%)</td>
<td>17 (59%)</td>
<td></td>
</tr>
<tr>
<td><strong>HGS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 1 tertile (n = 14)</td>
<td>3 (21%)</td>
<td>11 (79%)</td>
<td>0.293</td>
</tr>
<tr>
<td>&gt; 1 tertile (n = 38)</td>
<td>14 (37%)</td>
<td>24 (63%)</td>
<td></td>
</tr>
<tr>
<td><strong>SMIa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 1 tertile (n = 10)</td>
<td>6 (60%)</td>
<td>4 (40%)</td>
<td>0.018</td>
</tr>
<tr>
<td>&gt; 1 tertile (n = 22)</td>
<td>4 (18%)</td>
<td>18 (82%)</td>
<td></td>
</tr>
<tr>
<td><strong>SMDa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 1 tertile (n = 10)</td>
<td>5 (50%)</td>
<td>5 (50%)</td>
<td>0.123</td>
</tr>
<tr>
<td>&gt; 1 tertile (n = 22)</td>
<td>5 (23%)</td>
<td>17 (77%)</td>
<td></td>
</tr>
<tr>
<td><strong>Sarcopenia [n (%)]a</strong></td>
<td>1 (10%)</td>
<td>2 (9%)</td>
<td>0.935</td>
</tr>
<tr>
<td>Yes</td>
<td>9 (90%)</td>
<td>20 (91%)</td>
<td></td>
</tr>
</tbody>
</table>

*Pearson’s chi-square test; aUpper GIT: esophagus, stomach and pancreas tumors; without low weight: individuals with satisfactory weight/eutrophy, overweight and obesity; b=32.

BMI = body mass index; PG-SGA = patient-generated subjective global assessment; HGS = handgrip strength; SMI = skeletal muscle mass index; SMD = skeletal muscle radiodensity.

found low muscle mass in 100% of the sample, but only one female patient had sarcopenia43, nearly similar to the current study where only three patients had sarcopenia, revealing that the reduction of the muscle mass and strength were not concomitant for a large part of this sample.

Within the context of oncology44,45, it is widely described in the literature the close relation among muscle mass and clinical outcomes but studies evaluating all the required variables for the diagnosis of sarcopenia as suggested by the Consensus of Sarcopenia (strength, mass and muscle radiodensity) are scarce.

The evaluation of the muscle strength is the first criteria to assess sarcopenia, highlighting its importance8. A Brazilian study noticed that 22.6% of the patients with colorectal cancer presented low muscle mass, which has been shown to be an independent risk factor for postoperative complications47-49. A study evaluating sarcopenia in patients with gastric cancer submitted to surgery found low prevalence of HGS (32%) and sarcopenia (68%) and association among sarcopenia and postoperative complications and survival15.

The study limitations are: a) it was not possible to obtain CT of all the patients since it is a method utilized for diagnosis and cancer staging and part of the sample did not submit to this imaging test within the period of up to 30 days pre-outpatient consultation, which might have compromised the diagnosis of sarcopenia; b) the heterogeneity of the sample with individuals diagnosed with gastrointestinal tumor – pancreas, stomach, esophagus and colorectal – that have different characteristics with potential impact on the nutritional status.

In addition, the reduced sample did not favor the stratification by specific tumor sites as stomach, pancreas and esophagus cancers, it was necessary to group them as upper gastrointestinal tract tumors to allow comparisons of the nutritional status, SMI and SMD for different types of tumor. It is advised that the study findings should not be generalized to the population.

CONCLUSION

Decline of mass muscle and low weight occurred more frequently in the group of patients with upper GIT cancer than the colorectal cancer group; these findings can help to identify the types of tumor which can compromise the nutritional status more strongly and begin early nutritional intervention, but more studies are necessary to confirm the results.

In addition, longitudinal studies to evaluate the surgical impact on the body composition are required, contributing to the development of customized nutritional strategies for improved clinical outcomes.
ACKNOWLEDGMENTS

To Emanuelle Silva Russell and Leticia Cardoso Lemos for the invaluable contribution to data acquisition.

CONTRIBUTIONS

Juliane Alves da Silva, Viviane Dias Rodrigues and Nilian Carla Souza contributed to the study design, data collection, acquisition and/or interpretation, wording and/or critical review. Renata Brum Martucci contributed to the study design, wording and/or critical review. Andresa Couto and Aline Barcellos Barreto contributed to the analysis and/or interpretation of the data, wording and/or critical review. All the authors approved the final version to be published.

DECLARATION OF CONFLICT OF INTERESTS

There is no conflict of interests to declare.

FUNDING SOURCES

None.

REFERENCES


42. Shibutani M, Kashiwagi S, Fukuoka T, et al. Impact of perioperative nutritional status on long-term survival


Associate-editor: Lívia Costa de Oliveira. Orcid iD: https://orcid.org/0000-0002-5052-1846
Scientific-editor: Anke Bergmann. Orcid iD: https://orcid.org/0000-0002-1972-8777